Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $29.50 Consensus Price Target from Brokerages

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have been assigned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $29.50.

Several equities research analysts recently issued reports on the company. Citigroup boosted their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a report on Friday, August 9th. Truist Financial upped their target price on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Oppenheimer reaffirmed an “outperform” rating and set a $29.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, June 6th. Finally, HC Wainwright lifted their target price on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a report on Monday, August 12th.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $20.25 on Thursday. The company has a 50-day moving average of $17.62 and a two-hundred day moving average of $16.31. The firm has a market cap of $2.40 billion, a PE ratio of 37.50, a price-to-earnings-growth ratio of 3.30 and a beta of 0.70. Catalyst Pharmaceuticals has a 1-year low of $11.55 and a 1-year high of $20.87.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.13. The firm had revenue of $122.71 million during the quarter, compared to the consensus estimate of $111.76 million. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. Sell-side analysts anticipate that Catalyst Pharmaceuticals will post 1.82 EPS for the current fiscal year.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 7,541 shares of the firm’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $16.07, for a total value of $121,183.87. Following the sale, the insider now directly owns 18,427 shares in the company, valued at $296,121.89. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Carmen Jeffrey Del sold 7,541 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $16.07, for a total transaction of $121,183.87. Following the completion of the sale, the insider now owns 18,427 shares in the company, valued at approximately $296,121.89. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the completion of the transaction, the director now owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 288,599 shares of company stock worth $5,432,172. Corporate insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in CPRX. PVG Asset Management Corp acquired a new position in Catalyst Pharmaceuticals during the second quarter worth approximately $183,000. Point72 Asset Management L.P. grew its position in shares of Catalyst Pharmaceuticals by 47.9% during the second quarter. Point72 Asset Management L.P. now owns 618,296 shares of the biopharmaceutical company’s stock worth $9,577,000 after acquiring an additional 200,370 shares during the last quarter. Quarry LP increased its holdings in shares of Catalyst Pharmaceuticals by 170.0% in the 2nd quarter. Quarry LP now owns 16,334 shares of the biopharmaceutical company’s stock valued at $253,000 after acquiring an additional 10,284 shares during the period. Algert Global LLC purchased a new stake in Catalyst Pharmaceuticals in the 2nd quarter valued at $165,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Catalyst Pharmaceuticals in the 2nd quarter valued at $258,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.